Listed medtech Imricor Medical Systems was seeking to raise up to $35 million on Wednesday to see it through to US Food and Drug Administration approvals for its flagship product catered at the market for treatment of irregular heart rhythms.
The IP was licensed from Johns Hopkins University, according to fund-raising documents. Nic Walker
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
